Bleximenib (JNJ-75276617; Menin-MLL inhibitor 24) oxalate is a potent, selective and orally active menin-KMT2A protein-protein interaction inhibitor with IC 50 values of 0.1, 0.045, ≤0.066 nM for human, mouse, dog, respectively. Bleximenib oxalate shows antiproliferative activity and induces apoptosis . Bleximenib oxalate has the potential for the research of Acute myeloid leukemia (AML) .